|
注册号: Registration number: |
ChiCTR2500112460 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-14 09:44:30 |
|
注册时间: Date of Registration: |
2025-11-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
替妥尤单抗治疗甲状腺相关眼病的临床效:多中心前瞻性真实世界研究 |
|
Public title: |
Clinical Efficacy of Teprotumumab in the Treatment of Thyroid-Associated Ophthalmopathy: A Multicenter Prospective Real-World Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
替妥尤单抗治疗甲状腺眼病的临床疗效: 多中心前瞻性观察性登记性研究 |
|
Scientific title: |
Clinical Efficacy of Teprotumumab in the Treatment of Thyroid Eye Disease: A Multicenter Prospective Observational Registry Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
甘路 |
研究负责人: |
钱江 |
|
Applicant: |
Lu Gan |
Study leader: |
Jiang Qian |
|
申请注册联系人电话: Applicant telephone: |
+86 21 6437 7134 |
研究负责人电话:
Study leader's |
+86 21 6437 7134 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
ganlu1808@126.com |
研究负责人电子邮件: Study leader's E-mail: |
qianjiang@fudan.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市徐汇区汾阳路83号 |
研究负责人通讯地址: |
上海市徐汇区汾阳路83号 |
|
Applicant address: |
No. 83, Fenyang Road, Xuhui District, Shanghai |
Study leader's address: |
No. 83, Fenyang Road, Xuhui District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属眼耳鼻喉科医院 |
||
|
Applicant's institution: |
Eye and ENT hospital of Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属眼耳鼻喉科医院 |
||
|
Affiliation of the Leader: |
Eye and ENT hospital of Fudan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2025]伦审字第(2025135)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属眼耳鼻喉科医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Eye and ENT hospital of Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-06-20 00:00:00 | ||
|
伦理委员会联系人: |
吴仪菡 |
||
|
Contact Name of the ethic committee: |
Yihan Wu |
||
|
伦理委员会联系地址: |
上海市徐汇区汾阳路83号 |
||
|
Contact Address of the ethic committee: |
No. 83, Fenyang Road, Xuhui District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6437 7134 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
复旦大学附属眼耳鼻喉科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Eye and ENT hospital of Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市徐汇区汾阳路83号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 83, Fenyang Road, Xuhui District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中国研究型医院学会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Chinese Research Hospital Association |
||||||||||||||||||||||
|
研究疾病: |
甲状腺眼病 |
||||||||||||||||||||||
|
Target disease: |
Thyroid Eye Disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
评估替妥尤单抗对甲状腺眼病(Thyroid eye disease, TED)受试者的综合疗效;评估静脉滴注替妥尤单抗的安全性和耐受性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the comprehensive efficacy of Teprotumumab in subjects with Thyroid Eye Disease (TED); to assess the safety and tolerability of intravenous infusion of Teprotumumab. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.处于妊娠/哺乳期或近半年计划妊娠(不限性别); 2.基线听力受损:任一耳存在耳鸣或其他听力受损病史; 3.糖尿病血糖控制不佳:糖化血红蛋白≥ 9.0%; 4.近6个月内使用过利妥昔单抗; 5.近2个月内使用过托珠单抗; 6.对替妥尤单抗或药品成分中任何一种辅料过敏; 7.研究者评估认为有不适合参加本研究理由者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Pregnancy, lactation, or planning to become pregnant within the next six months (applicable to subjects of either sex). 2. Baseline hearing impairment: A history of tinnitus or other hearing impairment in either ear. 3. Poorly controlled diabetes mellitus: Glycated hemoglobin (HbA1c) ≥ 9.0%. 4. Previous use of Rituximab within the past 6 months. 5. Previous use of Tocilizumab within the past 2 months. 6. Known hypersensitivity to Teprotumumab or any excipient in the formulation. 7. Any other reason deemed by the investigator to make the subject unsuitable for participation in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-10-20 00:00:00至 To 2027-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-11-14 00:00:00 至 To 2026-04-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子病例记录表(eCRF)和电子采集和管理系统(EDC) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Case Record Form(eCRF) and Electronic Data Capture (EDC) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |